

ASX Announcement

12 November 2025

ASX Market Announcements
ASX Limited
20 Bridge Street
Sydney NSW 2000

Results of Annual General Meeting

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) (“NSB” or the “Company”) is pleased to advise in accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act, details of the resolutions and proxies received for the Annual General Meeting held on 12 November 2025.

All resolutions were determined by the conduct of a poll.

Proxies received and the results of the poll are shown in the Schedule attached.

This release has been approved for release by Chris Achurch on behalf of the Board of Directors.

Chris Achurch
Company Secretary

For more information, please contact:

Nathan Smith
Chief Executive Officer
NeuroScientific Biopharmaceuticals Ltd
ir@neuroscientific.com

Jane Morgan
Investor & Media Relations
Jane Morgan Management
jm@janemorganmanagement.com.au

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company's research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need.

Targeting Crohn's Disease with StemSmart™ Technology

Following the acquisition of Isopogen WA Ltd, NSB is prioritizing the application of its proprietary StemSmart technology through a SAS program targeting fistulising Crohn's disease—a severe and treatment-resistant form of the condition. Favourable outcomes will support the Company's progression to a Phase 2 clinical trial to further evaluate safety and preliminary efficacy in refractory and/or fistulising Crohn's disease. This initiative aligns with NSB's broader strategy to obtain regulatory and reimbursement approval for its MSC therapy both in Australia and internationally, with the goal of making the treatment available to patients with fistulising and refractory Crohn's disease, for whom current therapies remain inadequate.

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury. Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations.

Disclosure of Proxy Votes

NeuroScientific Biopharmaceuticals Limited

Annual General Meeting

Wednesday, 12 November 2025



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Remuneration Report	P	57,750,799	56,014,340 96.99%	79,400 0.14%	14,705	1,657,059 2.87%	61,996,783 99.87%	79,400 0.13%	14,705	-
2 Election of Director – Robert McKenzie	P	57,765,504	56,003,045 96.95%	101,000 0.17%	0	1,661,459 2.88%	75,472,849 99.87%	101,000 0.13%	5,781,475	Carried
3 Election of Director – Paul Fry	P	57,765,504	56,003,045 96.95%	101,000 0.17%	0	1,661,459 2.88%	81,254,324 99.88%	101,000 0.12%	0	Carried
4 Re-election of Director – Clarke Barlow	P	57,765,504	56,099,045 97.12%	5,000 0.01%	0	1,661,459 2.88%	81,350,324 99.99%	5,000 0.01%	0	Carried
5 Re-insertion of Proportional Takeover Bid Approval Provisions	P	57,765,504	56,043,845 97.02%	60,200 0.10%	0	1,661,459 2.88%	81,295,124 99.93%	60,200 0.07%	0	Carried
6a Ratification of issue of Incentive Options - 5,000,000 Incentive Options to Robert McKenzie	P	56,140,304	53,631,510 95.53%	847,335 1.51%	1,625,200	1,661,459 2.96%	59,618,353 98.60%	847,335 1.40%	1,625,200	Carried
6b Ratification of issue of Incentive Options - 5,000,000 Incentive Options to Paul Fry	P	56,140,304	53,631,510 95.53%	847,335 1.51%	1,625,200	1,661,459 2.96%	59,618,353 98.60%	847,335 1.40%	1,625,200	Carried
7 Approval of 10% Placement Facility	P	57,765,504	55,429,045 95.96%	675,000 1.17%	0	1,661,459 2.88%	80,680,324 99.17%	675,000 0.83%	0	Carried



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
8 Renewed approval of Employee Incentive Securities Plan	P	32,269,576	30,191,068 93.56%	417,049 1.29%	0	1,661,459 5.15%	36,177,911 98.86%	417,049 1.14%	0	Carried
9 Approval of potential termination benefits under the Plan	P	32,254,376	30,037,212 93.13%	555,705 1.72%	15,200	1,661,459 5.15%	36,024,055 98.48%	555,705 1.52%	15,200	Carried

